Key Takeaways JNJ beat Q2 estimates and raised 2025 guidance, while AZN met EPS estimates and maintained its outlook.JNJ's EPS estimate for 2025 rose to $10.86, while that for AZN increased modestly to$4.54.JNJ offers stronger growth visibility, lower valuation and a 3.2% dividend yield versus AZN's yield of 2.8%.Johnson & Johnson (JNJ) and AstraZeneca (AZN) rank among the world’s largest pharmaceutical companies, each with a broad and diversified healthcare portfolio. J&J operates primarily through its ph ...